Tosedostat

Drug Profile

Tosedostat

Alternative Names: CHR-2797

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Vernalis
  • Developer Azienda Ospedaliera Ospedali Riuniti Marche Nord; CTI BioPharma
  • Class Antineoplastics; Hydroxamic acids; Small molecules
  • Mechanism of Action Aminopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in United Kingdom (PO, Capsule)
  • 06 Dec 2015 Efficacy data from a phase II trial in Acute myeloid leukaemia presented at the Annual Meeting of the American Society of Hematology (ASH-2015)
  • 11 Aug 2015 No recent reports on development identified - Phase-II for Acute myeloid leukaemia (In the elderly, Monotherapy) in USA, Canada, Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top